Declining mortality from adult pneumococcal infections linked to children's vaccination

Journal of Infection

Volumn 72, Issue 4, 2016, Pages 439-449

  Grau, Imma ^a   Ardanuy, Carmen ^a   Cubero, Meritxell ^a   Benitez, Miguel A ^b   Liñares, Josefina ^a   Pallares, Roman ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Moises Broggi Hospital Sant Joan d'Espì   (Spain)

Author keywords

Mortality; Pneumococcal vaccines; Pneumonia; Serotypes; Streptococcus pneumoniae

Indexed keywords

BETA LACTAM ANTIBIOTIC; MACROLIDE; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGE; ALCOHOL CONSUMPTION; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SURVEILLANCE; HEART DISEASE; HERD IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MORTALITY RATE; PNEUMOCOCCAL INFECTION; PREVALENCE; SEROTYPE; SPAIN; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VACCINATION; ADOLESCENT; AGED; CHILD; EPIDEMIOLOGY; IMMUNOLOGY; MICROBIOLOGY; MIDDLE AGED; MORTALITY; PNEUMOCOCCAL INFECTIONS; RETROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; HUMANS; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RETROSPECTIVE STUDIES; SPAIN; STREPTOCOCCUS PNEUMONIAE; YOUNG ADULT;

EID: 84960809841     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2016.01.011     Document Type: Article

References (52)

1. Regev-Yochay G., Raz M., Dagan R., Porat N., Shainberg B., Pinco E., et al. Nasopharyngeal carriage of Streptococcus pneumoniae by adults and children in community and family settings. Clin Infect Dis 2004 Mar 1, 38(5):632-639.
2. Bogaert D., De Groot R., Hermans P.W. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 2004 Mar, 4(3):144-154.
3. 1-ST306. PLoS One 2012, 7:e42595.
4. Kyaw M.H., Rose C.E., Fry A.M., Singleton J.A., Moore Z., Zell E.R., et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis 2005, 192:377-386.
5. Klemets P., Lyytikäinen O., Ruutu P., Ollgren J., Nuorti J.P. Invasive pneumococcal infections among persons with and without underlying medical conditions: implications for prevention strategies. BMC Infect Dis 2008 Jul 22, 8:96.
6. Grau I., Pallares R., Tubau F., Schulze M.H., Llopis F., Podzamczer D., et al. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med 2005, 165(13):1533-1540.
7. van Hoek A.J., Andrews N., Waight P.A., Stowe J., Gates P., George R., et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 2012, 65:17-24.
8. Horácio A.N., Lopes J.P., Ramirez M., Melo-Cristino J. Non-invasive pneumococcal pneumonia in Portugal - serotype distribution and antimicrobial resistance. PLoS One 2014 Jul 30, 9(7):e103092. Portuguese Group for the Study of Streptococcal Infections.
9. Brueggemann A.B., Griffiths D.T., Meats E., Peto T., Crook D.W., Spratt B.G. Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J Infect Dis 2003 May 1, 187(9):1424-1432.
10. Sjöstrom K., Spindler C., Örqvist A., Kalin M., Sandgren A., Kühlmann-Berenzon K., et al. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis 2006, 42:451-459.
11. Hausdorff W.P., Feikin D.R., Klugman K.P. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 2005, 5:83-93.
12. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003 May 1, 348(18):1737-1746.
13. Lexau C.A., Lynfield R., Danila R., Pilishvili T., Facklam R., Farley M.M., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005, 294(16):2043-2051.
14. von Gottberg A., de Gouveia L., Tempia S., Quan V., Meiring S., von Mollendorf C., et al. GERMS-SA Investigators. Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med 2014 Nov 13, 371(20):1889-1899.
15. Moore M.R., Link-Gelles R., Schaffner W., Lynfield R., Lexau C., Bennett N.M., et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015 Mar, 15(3):301-309.
16. Waight P.A., Andrews N.J., Ladhani S.N., Sheppard C.L., Slack M.P., Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis 2015 May, 15(5):535-543.
17. Trampuz A., Widmer A.F., Fluckiger U., Haenggi M., Frei R., Zimmerli W. Changes in the epidemiology of pneumococcal bacteremia in a Swiss university hospital during a 15-year period, 1986-2000. Mayo Clin Proc 2004 May, 79(5):604-612.
18. Pallares R., Liñares J., Vadillo M., Cabellos C., Manresa F., Viladrich P.F., et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995 Aug 24, 333(8):474-480.
19. Harboe Z.B., Thomsen R.W., Riis A., Valentiner-Branth P., Christensen J.J., Lambertsen L., et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med 2009 May 26, 6(5):e1000081. 10.1371/journal.pmed.1000081.
20. Martens P., Worm S.W., Lundgren B., Konradsen H.B., Benfield T. Serotype-specific mortality from invasive Streptococcus pneumoniae disease revisited. BMC Infect Dis 2004 Jun 30, 4:21.
21. Alanee S.R., McGee L., Jackson D., Chiou C.C., Feldman C., Morris A.J., et al. Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an international study. Clin Infect Dis 2007 Jul 1, 45(1):46-51. International Pneumococcal Study Group.
22. Weinberger D.M., Harboe Z.B., Sanders E.A., Ndiritu M., Klugman K.P., Rückinger S., et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis 2010 Sep 15, 51(6):692-699.
23. Garau J., Calbo E. Capsular types and predicting patient outcomes in pneumococcal bacteremia. Clin Infect Dis 2007 Jul 1, 45(1):52-54.
24. Frazão N., Hiller N.L., Powell E., Earl J., Ahmed A., Sá-Leão R., et al. Virulence potential and genome-wide characterization of drug resistant Streptococcus pneumoniae clones selected in vivo by the 7-valent pneumococcal conjugate vaccine. PLoS One 2013 Sep 19, 8(9):e74867.
25. McCabe W.R., Jackson G.G. Gram-negative bacteremia. Etiology and ecology. Arch Intern Med 1962, 110(6):847-855.
26. Rolo D., Ardanuy C., Calatayud L., Pallares R., Grau I., García E., et al. Characterization of invasive pneumococci of serogroup 6 from adults in Barcelona, Spain, in 1994 to 2008. J Clin Microbiol 2011 Jun, 49(6):2328-2330.
27. Clinical Laboratory Standard Institute Performance standards for antimicrobial susceptibility testing; twenty-fourth informational suplement 2014, CLSI document M100-S24, Clinical and Laboratory Standards Institute, Wayne, PA.
28. De Carvalho Gomes H., Muscat M., Monnet D.L., Giesecke J., Lopalco P.L. Use of seven-valent pneumococcal conjugate vaccine (PCV7) in Europe, 2001-2007. Euro Surveill 2009 Mar 26, 14(12). pii: 19159.
29. Ciruela P., Soldevila N., Hernández S., Selva L., de Sevilla M.F., García-García J.J., et al. Risk factors for invasive pneumococcal disease in a community with a high proportion of non vaccine serotypes. Vaccine 2013 Jan 30, 31(6):960-966.
30. Henriques B., Kalin M., Ortqvist A., Olsson Liljequist B., Almela M., Marrie T.J., et al. Molecular epidemiology of Streptococcus pneumoniae causing invasive disease in 5 countries. J Infect Dis 2000 Sep, 182(3):833-839.
31. Web de l'Estadística Oficial de Catalunya. Institut d'Estadística de Catalunya. Available at: [accessed 07.03.15]. http://www.idescat.net.
32. Johnstone J., Eurich D.T., Minhas J.K., Marrie T.J., Majumdar S.R. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia. Clin Infect Dis 2010 Jul 1, 51(1):15-22.
33. Rueda A.M., Serpa J.A., Matloobi M., Mushtaq M., Musher D.M. The spectrum of invasive pneumococcal disease at an adult tertiary care hospital in the early 21st century. Med (Baltimore) 2010 Sep, 89(5):331-336.
34. Gattarello S., Borgatta B., Solé-Violán J., Vallés J., Vidaur L., Zaragoza R., et al. Decrease in mortality in severe community-acquired pneumococcal pneumonia: impact of improving antibiotic strategies (2000-2013). Chest 2014 Jul, 146(1):22-31. Community-Acquired Pneumonia en la Unidad de Cuidados Intensivos II Study Investigators.
35. Harbarth S., Garbino J., Pugin J., Romand J.A., Pittet D. Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis. Eur J Clin Microbiol Infect Dis 2005 Oct, 24(10):688-690.
36. Chokshi R., Restrepo M.I., Weeratunge N., Frei C.R., Anzueto A., Mortensen E.M. Monotherapy versus combination antibiotic therapy for patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2007 Jul, 26(7):447-451.
37. Garin N., Genné D., Carballo S., Chuard C., Eich G., Hugli O., et al. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med 2014 Dec, 174(12):1894-1901.
38. Postma D.F., van Werkhoven C.H., van Elden L.J., Thijsen S.F., Hoepelman A.I., Kluytmans J.A., et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 2015 Apr 2, 372(14):1312-1323.
39. Harboe Z.B., Valentiner-Branth P., Benfield T.L., Christensen J.J., Hjuler T., Kaltoft M., et al. Estimated effect of pneumococcal conjugate vaccination on invasive pneumococcal disease and associated mortality, Denmark 2000-2005. Vaccine 2008 Jul 4, 26(29-30):3765-3771.
40. Tsigrelis C., Tleyjeh I.M., Lahr B.D., Nyre L.M., Virk A., Baddour L.M. Decreases in case-fatality and mortality rates for invasive pneumococcal disease in Olmsted County, Minnesota, during 1995-2007: a population-based study. Clin Infect Dis 2008 Dec 1, 47(11):1367-1371.
41. van Hoek A.J., Andrews N., Waight P.A., George R., Miller E. Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes. PLoS One 2012, 7(7):e39150. 10.1371/journal.pone.0039150.
42. Ricketson L.J., Nettel-Aguirre A., Vanderkooi O.G., Laupland K.B., Kellner J.D. Factors influencing early and late mortality in adults with invasive pneumococcal disease in Calgary, Canada: a prospective surveillance study. PLoS One 2013 Oct 8, 8(10):e71924. 10.1371/journal.pone.0071924.
43. Burgos J., Falcó V., Borrego A., Sordé R., Larrosa M.N., Martinez X., et al. Impact of the emergence of non-vaccine pneumococcal serotypes on the clinical presentation and outcome of adults with invasive pneumococcal pneumonia. Clin Microbiol Infect 2013 Apr, 19(4):385-391.
44. Harboe Z.B., Dalby T., Weinberger D.M., Benfield T., Mølbak K., Slotved H.C., et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis 2014 Oct 15, 59(8):1066-1073.
45. Ruiz L.A., Zalacain R., Capelastegui A., Bilbao A., Gomez A., Uranga A., et al. Bacteremic pneumococcal pneumonia in elderly and very elderly patients: host- and pathogen-related factors, process of care, and outcome. J Gerontol A Biol Sci Med Sci 2014 Aug, 69(8):1018-1024. Epub 2014 Jan 27. 10.1093/gerona/glt288.
46. Jansen A.G., Rodenburg G.D., van der Ende A., van Alphen L., Veenhoven R.H., Spanjaard L., et al. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis 2009 Jul 15, 49(2):e23-e39.
47. Naucler P., Darenberg J., Morfeldt E., Ortqvist A., Henriques Normark B. Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia. Thorax 2013 Jun, 68(6):571-579.
48. Luján M., Burgos J., Gallego M., Falcó V., Bermudo G., Planes A., et al. Effects of immunocompromise and comorbidities on pneumococcal serotypes causing invasive respiratory infection in adults: implications for vaccine strategies. Clin Infect Dis 2013 Dec, 57(12):1722-1730.
49. Pulido M., Sorvillo F. Declining invasive pneumococcal disease mortality in the United States, 1990-2005. Vaccine 2010 Jan 22, 28(4):889-892.
50. Vila-Corcoles A., Ochoa-Gondar O. Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice. Drugs Aging 2013 May, 30(5):263-276.
51. Tomczyk S., Bennett N.M., Stoecker C., Gierke R., Moore M.N., Whitney C.G., et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014, 63:822-825.
52. Bonten M.J., Huijts S.M., Bolkenbaas M., Webber C., Patterson S., Gault S., et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015 Mar 19, 372(12):1114-1125.